Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency On Track to Initiate Phase 1/2 Global, Multi-Center Clinical Trial by Year End 2016 Most Advanced of Five Inherited Metabolic Disease Programs...
Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting NEW HAVEN, Conn., December 6, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs which function via targeted protein degradation,...
Deciphera Pharmaceuticals Reports Encouraging Clinical Results with DCC-2618 in Genetically-defined Cancers with Drug Resistant Mutations Waltham, MA | December 1, 2016 Advanced Kinase Inhibitors with Improved Tumor Targeting Offer Potential for Durable Responses in...
Arvinas Presents Data on its BET PROTAC Degraders at 2016 EORTC-NCI-AACR Symposium NEW HAVEN, Conn., November 29, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that data were presented...
Truveris Ranked Number 131 Fastest Growing Company in North America on Deloitte’s 2016 Technology Fast 500™ Nov 16, 2016 Truveris ranked 131 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences...
Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and...
Recent Comments